Concise review: umbilical cord blood transplantation: past, present, and future.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or quantitative synthesis
PubMed 25378655 · doi:10.5966/sctm.2014-0151
What was done
The authors conducted a concise narrative review summarizing the history, current clinical applications, and future directions of umbilical cord blood transplantation for hematological malignancies.
What was found
The abstract reports no quantitative data or numerical effect sizes. Qualitatively, it notes that cord blood transplantation offers faster availability of frozen units and avoids donor harvesting procedures. Compared with unrelated allogeneic stem cell transplantation, it is described as showing reduced relapse rates and comparable overall survival. Double-unit cord transplantation, alongside improved conditioning regimens, has addressed CD34-positive cell dose limitations to enable treatment in adults and larger pediatric patients.
Why it matters
Umbilical cord blood expands access to allogeneic transplantation for patients lacking fully matched donors. Double-unit strategies and advances in engraftment techniques have broadened the therapeutic window beyond small pediatric populations.
Limits
This is a narrative review with no systematic search criteria, quality appraisal, or meta-analytic data. The abstract provides no primary data, sample sizes, or quantitative risk estimates for engraftment, graft-versus-host disease, or survival outcomes.
Cited by
- supports A standard cord blood unit typically does not contain enough stem cells to successfully treat an adult bone marrow transplant recipient.